New dye technique may improve liver cancer surgery outcomes

NCT ID NCT07295275

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two ways of injecting a dye (ICG) during laparoscopic liver surgery for people with liver cancer. The dye helps surgeons see tumor edges more clearly. Researchers want to know if injecting the dye into an artery works better than the usual method of injecting it into the portal vein. The goal is to remove tumors more completely and reduce the chance of cancer coming back. About 200 adults aged 18-80 with liver cancer are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine Green (ICG) dye injected into an artery or portal vein during surgery
What this could lead to: If it works, this could point toward a safer, more effective surgical technique for removing liver tumors, potentially reducing cancer recurrence.
What could go wrong: This is a mid-stage study with 200 participants, so results may not apply to all patients. The dye injection routes carry risks like bleeding or infection, and the surgery itself is complex.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CANCER

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Beijing Municipality, China
West China Hospital
RECRUITING

Chengdu, Sichuan, 610041, China
Xuzhou Central Hospital
RECRUITING

Xuzhou, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.